You are here

Volastra Therapeutics

FDA grants fast track status for Volastra’s VLS-1488 to treat ovarian cancer

Pharmaceutical Business Review

Thu, 10/3/24 - 10:40 am

Volastra Therapeutics

platinum-resistant ovarian cancer

Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med

Fierce Biotech

Tue, 03/7/23 - 11:45 am

Volastra Therapeutics

With $44M and Microsoft R&D alliance, Volastra takes aim at metastatic cancers

MedCity News

Wed, 04/7/21 - 10:38 am

Volastra Therapeutics

cancer metastasis